bay2757556
Solid Tumors Harboring NTRK Fusion
BayerPhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Solid Tumors Harboring NTRK Fusion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Larotrectinib Bayer | Phase 1/2 | BB |
Selitrectinib Bayer | Phase 1 | CCC |
Ceritinib University of California, San Francisco | Phase 2 | CCC |
Entrectinib University of California, San Francisco | Phase 2 | CCC |
Regorafenib University of California, San Francisco | Phase 2 | CCC |
View all 13 →
Same molecule, other indications
bay2757556 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →